(Q37145410)

18 August 2017

1 reference

title

Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window (English)

1 reference

18 August 2017

0 references

1

John P Bilezikian

1 reference

18 August 2017

publication date

1 March 2008

1 reference

Current osteoporosis reports

18 August 2017

published in

1 reference

18 August 2017

volume

6

1 reference

18 August 2017

issue

1

1 reference

18 August 2017

page(s)

24-30

1 reference

https://scigraph.springernature.com/pub.10.1007/s11914-008-0005-9

18 August 2017

exact match

0 references

cites work

Treatment of postmenopausal osteoporotic women with parathyroid hormone 1-84 for 18 months increases cancellous bone formation and improves cancellous architecture: a study of iliac crest biopsies using histomorphometry and micro computed tomography

1 reference

12 December 2020

Osteosarcoma and teriparatide?

1 reference

12 December 2020

Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats

1 reference

12 December 2020

The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]

1 reference

12 December 2020

Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate

1 reference

12 December 2020

Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis

1 reference

12 December 2020

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

1 reference

12 December 2020

Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal

1 reference

12 December 2020

Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers.

1 reference

12 December 2020

Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis

1 reference

12 December 2020

Effects of Intermittent Parathyroid Hormone Administration on Bone Mineralization Density in Iliac Crest Biopsies from Patients with Osteoporosis: A Paired Study before and after Treatment

1 reference

12 December 2020

Daily and cyclic parathyroid hormone in women receiving alendronate

1 reference

12 December 2020

The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.

1 reference

12 December 2020

Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial

1 reference

12 December 2020

Risk of new vertebral fracture in the year following a fracture

1 reference

12 December 2020

Parathyroid hormone and periosteal bone expansion

1 reference

12 December 2020

On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism

1 reference

12 December 2020

The use of parathyroid hormone in the treatment of osteoporosis

1 reference

12 December 2020

Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.

1 reference

12 December 2020

Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis.

1 reference

12 December 2020

One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis

1 reference

12 December 2020

Quantitative computed tomographic assessment of the effects of 24 months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: results from the EUROFORS study

1 reference

12 December 2020

Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis

1 reference

12 December 2020

Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys

1 reference

12 December 2020

Efficacy and Safety of Human Parathyroid Hormone-(1–84) in Increasing Bone Mineral Density in Postmenopausal Osteoporosis

1 reference

12 December 2020

Recombinant Human Parathyroid Hormone (1–34) [Teriparatide] Improves Both Cortical and Cancellous Bone Structure

1 reference

12 December 2020

Mechanisms of anabolic therapies for osteoporosis

1 reference

12 December 2020

Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis

1 reference

12 December 2020

The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis

1 reference

12 December 2020

Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis

1 reference

12 December 2020

Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis

1 reference

12 December 2020

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

1 reference

12 December 2020

Comments on Initial experience with teriparatide in the United States

1 reference

12 December 2020

New anabolic therapies in osteoporosis

1 reference

12 December 2020

Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures

1 reference

12 December 2020

Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial

1 reference

12 December 2020

Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose

1 reference

12 December 2020

Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial

1 reference

12 December 2020

Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy.

1 reference

12 December 2020

Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment

1 reference

12 December 2020

The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis

1 reference

12 December 2020

10.1007/S11914-008-0005-9

Identifiers

DOI

1 reference

18 August 2017

1 reference